Upregulated FASN-mediated lipogenesis in senescent macrophages contributes to liver fibrosis progression - Report - MDSpire

Upregulated FASN-mediated lipogenesis in senescent macrophages contributes to liver fibrosis progression

  • By

  • Hongliang Dong

  • Chuanfang Shu

  • Ran Liu

  • Mingpei Zhao

  • Kaiyue Zhang

  • Ziqun Qu

  • Lili Wang

  • Jing Fan

  • Wei Ye

  • July 14, 2026

Share

Clinical Report: Increased FASN-driven lipogenesis in aged macrophages

Overview

This study investigates the role of senescent macrophages in liver fibrosis, highlighting increased fatty acid synthesis driven by FASN in aged macrophages.

Background

Liver fibrosis is a significant health concern, often resulting from chronic liver diseases and leading to severe complications such as cirrhosis. Macrophages are crucial in regulating liver inflammation and fibrosis, yet their senescence may exacerbate these conditions. Understanding the mechanisms by which senescent macrophages influence liver fibrosis is essential for developing targeted therapies.

Data Highlights

ParameterYoung MiceMiddle-aged Mice
Hepatic collagen depositionLess severeMore severe
FibrosisLess severeMore severe
Senescence markersLowerHigher

Key Findings

  • Middle-aged mice exhibited more severe hepatic collagen deposition and fibrosis compared to young mice.
  • Senescent macrophages showed increased expression of SASP components, including pro-inflammatory cytokines.
  • Conditioned medium from senescent macrophages activated LX-2 cells, indicating their role in HSC activation.
  • Transcriptome analysis revealed a shift towards fatty acid synthesis in senescent macrophages.
  • FASN protein degradation occurred via both ubiquitin-proteasome and autophagy pathways.

Clinical Implications

Understanding the metabolic reprogramming of macrophages could inform future strategies for managing chronic liver diseases.

Conclusion

The study highlights the significant role of senescent macrophages in liver fibrosis progression through FASN-driven lipogenesis.

Related Resources & Content

  1. Frontiers in Immunology, 2026 -- Targeting macrophages in liver fibrosis
  2. Frontiers in Immunology, 2026 -- Fatty Acid Metabolism and Lipid Channeling in Macrophages
  3. Journal of Gastroenterology -- Pathways Leading to Triglyceride Build-Up in Non-Alcoholic Fatty Liver Disease
  4. Frontiers in Immunology, 2026 -- Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages
  5. Clinical Practice Guidelines -- EASL CPGs management of MASLD
  6. New England Journal of Medicine, 2024 -- A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
  7. New England Journal of Medicine, 2025 -- Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
  8. Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial - PubMed
  9. Clinical Practice Guidelines
  10. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis | New England Journal of Medicine
  11. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis | New England Journal of Medicine
  12. Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial - PubMed

Original Source(s)

Related Content